Suscribirse

Humeral metastasis of renal cancer: Surgical options and review of literature - 11/06/18

Doi : 10.1016/j.otsr.2018.03.009 
R. Casadei, G. Drago , F. Di Pressa, D. Donati
 Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy 

Corresponding author. Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Via Pupilli 1, 40136 Bologna, BO, Italy.Department of Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Via Pupilli 1Bologna, BO40136Italy

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Introduction

The humerus is the second most common long bone site of metastatic disease from renal cell carcinomas (RCC) after femur. Surgery has an important role in the treatment of these lesions due to renal cell tumor's resistance to chemotherapy and radiotherapy.

Hypothesis

Prosthetic replacement is an effective and safe solution in treatment of renal humeral metastasis.

Material and methods

Fifty-six patients affected by RCC bone metastases of the humerus that underwent a surgical reconstruction were rewised. Thirty-five lesions were localized on proximal third, 12 on the shaft, 9 on distal third. Among proximal 29 were treated with resection and endoprosthetic replacement and 6 with plate and cement. Six diaphyseal lesions were stabilized with intramedullary nailing, 5 with plate and cement and 1 with an intercalary prosthesis. Regarding distal lesions, 7 elbow prostheses and 2 plates and cement were used.

Results

The average age was 63years. Metastasis was single in 55% of cases, and in 45% metachronous. A pathologic fracture (PF) occurred in 64% of cases. Only 9% of patients had a mechanical complication, 7% an infection and 5% neurological deficit. A local recurrence occurred in 14% of patients. An implant failure has been observed in 10 patients, 5 for mechanical complications, 2 for infections and 3 for local recurrence; of these 7 were treated with a prosthesis and 3 with plate and cement. The mean value of MSTS score was 64%, 63% and 59% respectively in patients with proximal, diaphyseal and distal humerus metastases.

Discussion

Solitary and metachronous bone metastases have a longer survival. Disease-free interval>2years is another important prognostic factor. Reconstruction with a modular prosthesis is recommended in proximal and distal third. Instead in diaphyseal lesions a closed reduction and fixation with intramedullary locked nailing are preferred. When surgical indications are correctly followed, good oncologic and functional outcomes are obtained, leading to markedly improvement of patients’ quality of life.

Retrospective study

Level of evidence: IV.

El texto completo de este artículo está disponible en PDF.

Keywords : Humerus, Tumor, Renal Cancer, Metastasis, Pathological fracture


Esquema


© 2018  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 104 - N° 4

P. 533-538 - juin 2018 Regresar al número
Artículo precedente Artículo precedente
  • Collection and reconstruction after harvesting donor tissues from the musculoskeletal system: Technique specific to the lower limbs
  • R. Erivan, G. Villatte, T. Lecointe, S. Descamps, S. Boisgard
| Artículo siguiente Artículo siguiente
  • Effect of early fasting and total parenteral nutrition support on the healing of incision and nutritional status in patients after sacrectomy
  • S. Gao, Y. Zheng, X. Liu, Z. Tian, Y. Zhao

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.